Targeting Androgen Receptor Phase Separation to Overcome Antiandrogen Resistance

Scientists conducted a phase-separation-based phenotypic screen and identified ET516 that specifically disrupted androgen receptor (AR) condensates, effectively suppressed AR transcriptional activity, and inhibited the proliferation and tumor growth of prostate cancer cells expressing AR-resistant mutants.